GTBP•benzinga•
EXCLUSIVE: GT Biopharma Tells Benzinga Co. Advances GTB-3650 Phase I Trial To Cohort 2 Following Successful Initial Human Dosing And Evidence Of Early Immune Activation Signals
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 19, 2025 by benzinga